Henry J. Kaiser Family Foundation
• International News
Zimbabwe Pharmaceutical Company Begins Production of Generic Antiretroviral Drugs

June 9, 2004

A Harare, Zimbabwe-based pharmaceutical company on Tuesday said it has begun producing generic antiretroviral drugs for use by HIV-positive people in the country, AFP/Independent Online reports. Varichem Pharmaceuticals said in a statement that it believes it is the first company in Africa to manufacture antiretrovirals, according to AFP/Independent Online. The company is producing nine different drugs using raw materials imported from European and Asian countries, AFP/Independent Online reports. More than 3,000 people die of AIDS-related causes each week in Zimbabwe, which has one of the highest HIV prevalence rates in the world at 24.9%. Earlier this year, the Zimbabwean government announced a pilot project to distribute antiretroviral drugs at no cost to patients in select government hospitals. According to officials, about 70% of patients in Zimbabwe's hospitals are HIV-positive. The domestic production of antiretroviral drugs is expected to "significant[ly]" reduce the cost of the medications, according to AFP/Independent Online. Former Zambian President Kenneth Kaunda and Zimbabwean President Robert Mugabe next week are expected to address Zimbabwe's first-ever national AIDS conference, AFP/Independent Online reports (AFP/Independent Online, 6/8).

Back to other news for June 9, 2004

Search the Newsroom archive


Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2004 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.


This article was provided by Henry J. Kaiser Family Foundation
, and is a part of the publication Kaiser Daily HIV/AIDS Report.